Fourth-quarter profits at high-flying Genentech soared 64 percent, but analysts were chilled by the news that revenue from its best-selling Avastin hadn't reached their lofty projections. Genentech's stock dropped 3 percent, despite Avastin's $359 million score for the fourth quarter, an 89 percent rise. Analysts were looking for $381 million. Report